FindTrial
Sign In

A randomized, double blind, placebo controlled, parallel group study to determine the effect of BXL628 in patients with Chronic Non-Bacterial Prostatitis category III Chronic Pelvic Pain Syndrome, CP/CPPS

A randomized, double blind, placebo controlled, parallel group study to determine the effect of BXL628 in patients with Chronic Non-Bacterial Prostatitis category III Chronic Pelvic Pain Syndrome, CP/CPPS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001849-42-IT
Enrollment
120
Registered
2005-12-20
Start date
2005-07-13
Completion date
Unknown
Last updated
2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Non-Bacterial Prostatitis category III Chronic Pelvic Pain Syndrome, CP/CPPS MedDRA version: 6.1 Level: PT Classification code 10036978

Interventions

Product Name: BXL628 Product Code: BXL628 Pharmaceutical Form: Capsule, soft CAS Number: 199798-84-0 Current Sponsor code: BXL628 Concentration unit: µg microgram(s) Concentration type: equal Concentr

Sponsors

BIOXELL SPA
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026